- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07873619
Histotripsy for Peritoneal Tumour and Lymph Node: a Pilot Study
Peritoneal cancer is tricky to be managed. It is not easy to be detected or diagnosed at early stage without symptom, or with common symptoms of many diseases or discomfort and often leads to advance stage at time of diagnosis with few treatment options and limited life span. It is also challenging to handle peritoneal tumour as it usually involves large area in peritoneum, or spread widely throughout the surface of peritoneum if metastatic from other origins. Systemic therapy is the common way to treat peritoneal cacner if the disease is inoperable. However, the unsatisfied penetration rate significantly limits the anti-tumour effect of intraperitoneal chemotherapy even after various attempts and most approaches demonstrated limited efficiency. Effective treatment for peritoneal cancer is still scarce and necessary. While the tumour nature of peritoneal tumour consists of solid tumour and soft tissue tumour, depends on primary or secondary disease, Histotripsy, which can be used on most kinds of solid tumour as well as soft tissue tumour, may yield a new direction and insight on peritoneal cancer management.
Histotripsy is currently indicated for liver tumours, approved by FDA and has been investigated for many disease types in preclinical researches and carried out several clinical trials for liver tumour, benign prostatic hyperplasia, liver tumour combined with systemic therapy, renal tumour, pancreatic tumour, soft tissue tumours, abdominal tumour, calcific aortic valves, and pain in plantar fasciitis, with encouraging results in some clinical trials. As most clinical trials above are for solid tumour and soft tissue tumour that suit the tumour nature of peritoneal tumour, we believe that Histotripsy is also safe and feasible on human with peritoneal tumour. Considering nodal involvement also frequently comes with peritoneal cancer, we would like to conduct an investigation for Histotripsy in peritoneal tumour and lymph node.
Although the result of clinical trial in peritoneal tumour and lymph node are not available yet, HIFU (High Intensity Focused Ultrasound) as another non-invasive ablation also delivered by ultrasound wave which has been in clinical use for many years worldwide can be referenced for Histotripsy. The core difference of HIFU and Histotripsy is, HIFU employs thermal energy to induce coagulative necrosis, while Histotripsy utilises mechanical cavitation to disrupt tumour tissues and preserves adjacent critical structure without the issue of heat, which makes it safer than HIFU. According to some reviews of HIFU, it is obvious that HIFU is feasible and safe without significant adverse event for abdominal tumours including peritoneal tumour and lymph node. Consequently, Histotripsy as a non-thermal ablation and is considered to be safer than HIFU, should also be feasible and safe for peritoneal tumour and lymph node. Hence, it is time for Hong Kong to launch the investigation on the feasibility, safety, and efficacy of Histotripsy in peritoneal tumour and lymph node.
Přehled studie
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Albert Chan, MBBS, MS
- Telefonní číslo: +85222553025
- E-mail: acchan@hku.hk
Studijní místa
-
-
-
Hong Kong, Hongkong, 0000
- Nábor
- The University of Hong Kong
-
Dílčí vyšetřovatel:
- Vince Lau, MBBS
-
Kontakt:
- Albert Chan, MBBS, MS
- Telefonní číslo: +85222553025
- E-mail: acchan@hku.hk
-
Vrchní vyšetřovatel:
- Albert Chan, MBBS, MS
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Age ≥ 18 years old
-
Fit for general anaesthesia
-
Peritoneal tumour (eg. intraperitoneal tumour, retroperitoneal tumour) and/or lymph node
-
Size ≤ 10cm for each peritoneal tumour and lymph node
-
With or without distant metastasis
-
Good performance status
- Tumour visible and targetable by ultrasound with acceptable acoustic windows
- Adequate hematologic, hepatic, and renal function
Exclusion Criteria:
- Refusal to take part in clinical trial
- Not fit for general anaesthesia
- Poor general condition with limited life expectancy
- Uncontrolled coagulopathy
- Extensive bowel interposition preventing safe targeting, per recent porcine safety data linking mis-targeting to bowel injury
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Jiný: Histotripsy
Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures |
Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures. It works by using high-intensity ultrasound waves to create microscopic bubbles within the tumour tissue. These bubbles rapidly expand and collapse, generating shock waves that disrupt the tissue. The technique is highly precise and can be targeted to specific areas of the liver, allowing for selective destruction of tumour cells while minimizing damage to healthy tissue. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
post procedure events
Časové okno: duration of hospital stay, normally 3 days on average
|
safety monitoring |
duration of hospital stay, normally 3 days on average
|
|
number of case proceed with Histotripsy
Časové okno: 1 day after procedure
|
feasibility of doing histotripsy for peritoneal tumour and/or lymph nodes |
1 day after procedure
|
|
changes in tumour features
Časové okno: up to 3 years
|
changes in tumour size with serial interval scans |
up to 3 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Questionnaire based pain assessment
Časové okno: 2 days
|
to evaluate patient-reported pain level before and after Histotripsy |
2 days
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- GHK-2026-006
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .